Unknown

Dataset Information

Harnessing Greater Statistical Power: Comprehensive Evaluation of Disease Modifying Treatment Effects Across All or Multiple Post-Baseline Visits Compared to the Last Visit for Alzheimer's Disease Clinical Trials.


ABSTRACT:

Background

In Alzheimer's disease (AD) clinical trials, efficacy inference is traditionally based on the last visit (e.g., 18 months). However, recent studies suggest that disease-modifying treatment effects may emerge as early as 3 months post-baseline.

Objective

To explore this further, our study aimed to assess the increased statistical power achieved by incorporating all or multiple post-baseline visits to estimate treatment effect, compared to relying solely on the last visit.

Methods

We developed explicit formulas for the base functions of the natural cubic spline model, ensuring compatibility with standard SAS procedures. Through simulations using disease progression trajectories from ClarityAD and TRAILBLAZER-ALZ2 trials, we comprehensively evaluated various m

SUBMITTER: Wang G 

PROVIDER: S-EPMC11875270 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature